Skip to main content
SpringerLink
Log in

Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rationale

5-HT receptor mechanisms have been suggested to mediate improvements in cognition in schizophrenia.

Aim

The aim of this study was to investigate the involvement of 5-HT receptor mechanisms in sub-chronic phencyclidine (PCP)-induced reversal learning deficits in female rats, a task of relevance to schizophrenia.

Methods

Adult female hooded Lister rats were trained to perform an operant reversal learning task and then received sub-chronic PCP (2 mg/kg) or vehicle intraperitoneally (i.p.) twice daily for 7 days, followed by 7-day washout. Rats then received an acute dose of the 5-HT7 receptor antagonist SB-269970A (1.0, 3.0, and 10.0 mg/kg, i.p.) or vehicle. In experiment 2, PCP-treated rats received the selective 5-HT2C receptor antagonist, SB-243213A acutely (1.0, 3.0, and 10.0 mg/kg, i.p.) or vehicle. In experiment 3, PCP-treated rats received the 5-HT1A receptor partial agonist, buspirone (0.15625, 0.3125, and 0.625 mg/kg, i.p.) in combination with the selective 5-HT1A receptor antagonist WAY-100635 (0.3 and 1.0 mg/kg).

Results

In all experiments, sub-chronic PCP significantly impaired reversal phase performance (P < 0.01–0.001), with no effect in the initial phase. SB-269970A at 3.0 and 10.0 mg/kg significantly improved the PCP-induced deficit (P < 0.05). SB-243213A also significantly attenuated the deficit at 10 mg/kg (P < 0.05). In experiment 3, buspirone attenuated the deficit with significant effects at 0.3125 and 0.625 mg/kg (P < 0.05). WAY-100635 at 0.3 and 1.0 mg/kg produced a partial attenuation of buspirone’s effect as buspirone (0.3125 mg/kg) in the presence of WAY-100635 did not significantly reverse the PCP-induced deficit.

Conclusions

These studies implicate the role of 5-HT7, 5-HT2C, and 5-HT1A receptors in the improvement of cognitive dysfunction of relevance to schizophrenia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  • Abdul-Monim Z, Reynolds GP, Neill JC (2003) The atypical antipsychotic ziprasidone, but not haloperidol, improves PCP-induced cognitive deficits in a reversal learning task in the rat. J Psychopharmacol 17:57–66

    Article  PubMed  CAS  Google Scholar 

  • Abdul-Monim Z, Reynolds GP, Neill JC (2006) The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Behav Brain Res 169:263–273

    Article  PubMed  CAS  Google Scholar 

  • Abdul-Monim Z, Reynolds GP, Neill JC (2007) Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alteration in parvalbumin-immunoreactive expression in the rat. J Psychopharmacol 21:198–205

    Article  PubMed  CAS  Google Scholar 

  • Abramowski D, Rigo M, Duc D, Hoyer D, Staufenbiell M (1995) Localization of the 5-hydroxytryptamine2C receptor protein in human and rat brain using specific antisera. Neuropharmacology 34:1635–1645

    Article  PubMed  CAS  Google Scholar 

  • Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC et al (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686–96

    PubMed  CAS  Google Scholar 

  • Azmitia EC, Gannon PJ, Kheck NM, Whitaker-Azmitia PM (1996) Cellular localisation of the 5-HT1A receptor in primate brain neurons and glial cells. Neuropsychopharmacology 14:35–46

    Article  PubMed  CAS  Google Scholar 

  • Barnes NM, Sharp T (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38:1083–1152

    Article  PubMed  CAS  Google Scholar 

  • Beasley CL, Zhang ZJ, Patten I, Reynolds GP (2002) Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia: defined by the presence of calcium-binding proteins. Biol Psychiatry 52:708–715

    Article  PubMed  CAS  Google Scholar 

  • Benes FM, Berretta S (2001) GABAergic interneurones: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 25:1–27

    Article  PubMed  CAS  Google Scholar 

  • Benes FM, McSparren J, Bird ED, San Giovanni JP, Vincent SL (1991) Deficits in small interneurons in prefrontal and cingulated cortices of schizophrenic and schizoaffective patients. Arch Gen Psychiatry 48:996–1001

    PubMed  CAS  Google Scholar 

  • Blackburn TP, Minabe Y, Middlemiss DN, Shirayama Y, Hashimoto K, Ashby CR Jr (2002) Effect of acute and chronic administration of the selective 5-HT2C receptor antagonist SB-243213 on midbrain dopamine neurons in the rat: an in vivo extracellular single cell study. Synapse 46:129–139

    Article  PubMed  CAS  Google Scholar 

  • Bonhaus DW, Weinhardt KK, Taylor M, DeSouza A, McNeeley PM, Szczepanski K et al (1997) RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist. Neuropharmacology 36:621–629

    Article  PubMed  CAS  Google Scholar 

  • Boulougouris V, Dalley JW, Robbins TW (2007) Effects of orbitofrontal, infralimbic and prelimbic cortical lesions on serial spatial reversal learning in the rat. Behav Brain Res 179:219–228

    Article  PubMed  Google Scholar 

  • Boulougouris V, Glennon JC, Robbins TW (2008) Dissociable effects of selective 5-HT2A and 5-HT2C receptor antagonists on serial spatial reversal learning in rats. Neuropsychopharmacology 33:2007–2019

    Article  PubMed  CAS  Google Scholar 

  • Bromidge SM, Dabbs S, Davies DT et al (2000) Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(methyl-3 ppyridyl)oxy]-5-pyridyl]carbamoyl]-6-trifluoromethyl-indoline (SB-243213) as a potential antidepressant/anxiolytic agent. J Med Chem 43:23–34

    Article  CAS  Google Scholar 

  • Burnet PW, Eastwood SL, Harrison PJ (1997) 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 15:442–455

    Article  Google Scholar 

  • Caccia S, Conti I, Vigano G, Garattini S (1986) 1-(2-pyrimidinyl)-piperazine as active metabolite of buspirone in man and rat. Pharmacology 33:46–51

    Article  PubMed  CAS  Google Scholar 

  • Di Matteo V, De Blasi A, Di Giulio C, Esposto E (2001) Role of 5-HT(2C) receptors in the control of central dopamine function. Trends Pharmacol Sci 22:229–232

    Article  PubMed  Google Scholar 

  • Di Matteo V, Di Giovanni G, Di Mascio M, Esposito E (1999) SB242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system. Neuropharmacology 38:1195–1205

    Article  PubMed  Google Scholar 

  • Eberle-Wang K, Mikeladze Z, Uryu K, Chesselet MF (1997) Pattern of expression of the serotonin2C receptor messenger RNA in the basal ganglia of adult rats. J Comp Neurol 384:233–247

    Article  PubMed  CAS  Google Scholar 

  • Elvevag B, Goldberg TE (2000) Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol 14:1–21

    PubMed  CAS  Google Scholar 

  • Galici R, Boggs JD, Miller KL, Bonaventure P, Atack JR (2008) Effects of SB-269970, a 5-HT7 receptor antagonist, in mouse models predictive of antipsychotic-like activity. Behav Pharmacol 19:153–159

    Article  PubMed  CAS  Google Scholar 

  • Gobert A, Rivet JM, Cistarelli L, Melon C, Millan MJ (1999) Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin1A receptors and blockade of alpha2-adrenergic receptors underlie its actions. Neuroscience 93:1251–1262

    Article  PubMed  CAS  Google Scholar 

  • Gobert A, Rivet JM, Lejeune F, Newman-Tancredi A, Adhumeau-Auclair A, Nicolas J et al (2000) Serotonin2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. Synapse 36:205–221

    Article  PubMed  CAS  Google Scholar 

  • Gold JM, Goldberg TE, Kleinman JE, Weinberger DR (1991) The impact of symptomatic state pharmacological treatment on cognitive function of patients with schizophrenia and mood disorders. In: Mohr E, Brower P (eds) Handbook of clinical trials. The Neurobehavioral and injury. Swetz and Zeitlinger, Amsterdam, pp 185–214

    Google Scholar 

  • Gray JA, Roth BL (2007) Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull 33:1100–1119

    Article  PubMed  Google Scholar 

  • Grayson B, Idris NF, Neill JC (2007) Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the NOR task in the rat. Behav Brain Res 184:31–38

    Article  PubMed  CAS  Google Scholar 

  • Hagan JJ, Price GW, Jeffery P, Deeks NJ, Stean T, Piper D et al (2000) Characterization of SB-269970-A, a selective 5-HT7 receptor antagonist. Br J Pharmacol 130:539–548

    Article  PubMed  CAS  Google Scholar 

  • Hagiwara H, Fujita Y, Ishima T et al (2008) Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptors. Eur Neuropsychopharmacol 18:448–454

    Article  PubMed  CAS  Google Scholar 

  • Hamik A, Oksenberg D, Fischette C, Peroutka SJ (1990) Analysis of tandospirone (SM-3997) interactions with neurotransmitter binding sites. Biol Psychiatry 28:99–109

    Article  PubMed  CAS  Google Scholar 

  • Harvey PD, Meltzer H, Simpson GM, Potkin SG, Loebel A, Siu C, Romano SJ (2004) Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res 66:101–113

    Article  PubMed  Google Scholar 

  • Haut MW, Cahill J, CutlipWD SJM, Makela EH, Bloomfield SM (1996) On the nature of Wisconsin Card Sorting Test performance in schizophrenia. Psychiatry Res 65:15–22

    Article  PubMed  CAS  Google Scholar 

  • Hedlund PB, Sutcliffe JG (2004) Functional, molecular and pharmacological advances in 5-HT7 receptor research. Trends Pharmacol Sci 25:481–6

    Article  PubMed  CAS  Google Scholar 

  • Heinrichs RW (2005) The primacy of cognition in schizophrenia. Am Psychol 60:229–242

    Article  PubMed  Google Scholar 

  • Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY (2001) 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76:1521–1531

    Article  PubMed  CAS  Google Scholar 

  • Ichikawa J, Meltzer HY (1990) The effect of chronic clozapine and haloperidol on basal dopamine release and metabolism in rat striatum and nucleus accumbens studied by in vivo microdialysis. Eur J Pharmacol 176:371–374

    Article  PubMed  CAS  Google Scholar 

  • Idris NF, Repeto P, Neill JC, Large CH (2005) Investigation of the effects of lamotrigine and clozapine in improving reversal-learning impairments induced by acute phencyclidine and D-amphetamine in the rat. Psychopharmacology 179:336–348

    Article  PubMed  CAS  Google Scholar 

  • Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301–8

    PubMed  CAS  Google Scholar 

  • Jentsch JD, Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201–25

    Article  PubMed  CAS  Google Scholar 

  • Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW (2006) Randomized controlled trial of effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63:1079–87

    Article  PubMed  CAS  Google Scholar 

  • Kapur S, Remington G (1996) Serotonin–dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153:466–476

    PubMed  CAS  Google Scholar 

  • Kapur S, Zipursky RB, Remington G (1999) Clinical and therapeutic implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156:286–293

    PubMed  CAS  Google Scholar 

  • Keefe RS, Bilder RM, Davis SM (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 64:633–647

    Article  PubMed  CAS  Google Scholar 

  • Kuperberg G, Heckers S (2000) Schizophrenia and cognitive function. Curr Opin Neurobiol 10:205–210

    Article  PubMed  CAS  Google Scholar 

  • Lewis SW, Barnes TRE, Davies L, Murray RM, Dunn G, Hayhurst KP, Markwick A, Lloyd H, Jones PB (2006) Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 32:715–23

    Article  PubMed  Google Scholar 

  • Lieberman JA (2006) What the CATIE study means for clinical practice. Psychiatr Serv 57:1075

    Article  PubMed  Google Scholar 

  • Mahe C, Loetscher E, Feuerbach D, Muller W, Seiler MP, Schoeffter P (2004) Differential inverse agonist efficacies of SB-258719, SB-258741 and SB-269970 at human recombinant serotonin 5-HT7 receptors. Eur J Pharmacol 495:97–102

    Article  PubMed  CAS  Google Scholar 

  • Marder SR, Fenton W (2004) Measurement and treatment research to improve cognition in schizophrenia: NIMH MATRIICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res 72:5–9

    Article  PubMed  Google Scholar 

  • McAlonan K, Brown VJ (2003) Orbital prefrontal cortex mediates reversal learning and not attentional set shifting in the rat. Behav Brain Res 146:97–103

    Article  PubMed  Google Scholar 

  • McLean SL, Shemar GK, Idris NF, Marshall KM, Neill JC (2007) Deficits in attentional set-shifting in rats following sub-chronic phencyclidine (PCP) administration, effect of gender. Eur Neuropsychopharmacol 17(Suppl 4):S275

    Article  Google Scholar 

  • McLean SL, Beck JP, Woolley ML, Neill JC (2008a) A preliminary investigation into the effects of antipsychotics on sub-chronic phencyclidine-induced deficits in attentional set-shifting in female rats. Behav Brain Res 189:152–158

    Article  PubMed  CAS  Google Scholar 

  • McLean SL, Woolley ML, Neill JC (2008b) Phencyclidine-induced reversal learning deficits in rats; role of 5-HT2C and 5-HT1A receptors. Program No. 291.9/RR84. 2008 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2008. Online

  • McLean SL, Idris NF, Woolley ML, Neill JC (2009) D(1)-like receptor activation improves PCP-induced cognitive deficits in animal models: implications for mechanisms of improved cognitive function in schizophrenia. Eur Neuropsychopharmacol 19:440–450

    Article  PubMed  CAS  Google Scholar 

  • Meltzer HY (1995) Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci 3:64–75

    PubMed  CAS  Google Scholar 

  • Meltzer HY (1999) The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21(2 Suppl):106S–115S

    PubMed  CAS  Google Scholar 

  • Meltzer HY, Matsubara S, Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251:238–246

    PubMed  CAS  Google Scholar 

  • Meneses A (2004) Effects of the 5-HT7 receptor antagonists SB-269970 and DR 4004 in autoshaping Pavlovian/instrumental learning task. Behav Brain Res 155:275–282

    Article  PubMed  CAS  Google Scholar 

  • Miyamoto S, Duncan GE, Marx CE, Lieberman (2005) Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotics drugs. Mol Psychiatry 10:79–104

    Article  PubMed  CAS  Google Scholar 

  • Neill JC, Idris NF, Arnt J (2008) Sertindole, 5-HT2A and 5-HT6 antagonists improve a subchronic phencyclidine-induced reversal learning deficit in rats. Schizophr Res 102:60

    Google Scholar 

  • Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verriele L, Audinot V, Millan MJ (1998) Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35]GTPgS binding study. Eur J Psychopharmacol 355:245–256

    CAS  Google Scholar 

  • Pantelis C, Barber FZ, Barnes TRE, Nelson HE, Owen AM, Robbins TW (1999) Comparison of set shifting ability in patients with chronic schizophrenia and frontal lobe damage. Schizophr Res 37:251–70

    Article  PubMed  CAS  Google Scholar 

  • Pompeiano M, Palacios JM, Mengod G (1994) Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors. Brain Res Mol Brain 23:163–178

    Article  CAS  Google Scholar 

  • Pouzet B, Didriksen M, Arnt J (2002) Effects of the 5-HT7 receptor antagonist SB-258741 in animal models for schizophrenia. Pharmacol Biochem Behav 71:655–665

    Article  PubMed  CAS  Google Scholar 

  • Prinssen EPM, Kleven MS, Koek W (1999) Interactions between neuroleptics and 5-HT1A ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects. Psychopharmacology 1444:20–29

    Article  Google Scholar 

  • Protais P, Chagraoui A, Arbaoui J (1994) Dopamine receptor antagonist properties of S 14506, 8-OH-DPAT, raclopride and clozapine in rodent. Eur J Pharmacol 271:167–173

    Article  PubMed  CAS  Google Scholar 

  • Purdon SE, Jones BDW, Stip E, Labelle A, Addington D, David SR, Breier A, Tollefson GD (2000) Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry 57:249–258

    Article  PubMed  CAS  Google Scholar 

  • Reichenberg A, Weiser M, Caspi A et al (2006) Premorbid intellectual functioning and risk of schizophrenia and spectrum disorders. J Clin Exp Neuropsychol 28:193–207

    Article  PubMed  Google Scholar 

  • Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y et al (1994) Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268:1403–1410

    PubMed  CAS  Google Scholar 

  • Roth BL, Hanizavareh SM, Blum AE (2004) Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology 174:17–24

    Article  PubMed  CAS  Google Scholar 

  • Roth BL, Sheffler D, Potkin SG (2003) Atypical antipsychotic drug actions: unitary or multiple mechanisms for “atypicality”? Clin Neurosci Res 3:108–117

    Article  CAS  Google Scholar 

  • Schechter LE, Dawson LA, Harder JA (2002) The potential utility of 5-HT1A receptor antagonists in the treatment of cognition in Alzheimer’s disease. Curr Pharm Des 8:139–145

    Article  PubMed  CAS  Google Scholar 

  • Schiapparelli L, Simon AM, Del Rio J, Frechilla D (2006) Opposing effects of AMPA and 5-HT(1A) receptor blockade on passive avoidance and object recognition performance: correlation with AMPA receptor subunit expression in the rat hippocampus. Neuropharmacology 50:897–907

    Article  PubMed  CAS  Google Scholar 

  • Semenova S, Geyer MA, Sutcliffe JG, Markou A, Hedlund PB (2008) Inactivation of the 5-HT7 receptor partially blocks phencyclidine-induced disruption of prepulse inhibition. Biol Psychiatry 63:98–105

    Article  PubMed  CAS  Google Scholar 

  • Shahid M, Walker GB, Zorn SH, Wong EHF (2009) Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 23:65–73

    Article  PubMed  CAS  Google Scholar 

  • Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400–1411

    Article  PubMed  CAS  Google Scholar 

  • Siegfried SL, Fleischacker W, Liberman JA (2001) Pharmacological treatment of schizophrenia. In: Lieberman JA, Murray RM (eds) Comprehensive care of schizophrenia, a textbook of clinical management. Martin Dunitz, London

    Google Scholar 

  • Smith MI, Piper DC, Duxon MS, Upton N (2002) Effect of SB-243213, a selective 5-HT2C receptor antagonist, on the rat sleep profile: a comparison to paroxetine. Pharmacol Biochem Behav 71:599–605

    Article  PubMed  CAS  Google Scholar 

  • Snigdha S, Neill J, Shahid M, Cruise L, Henry B (2007) Brain-derived neurotrophic factor down-regulation in rat brain following sub-chronic phencyclidine administration. Eur Neuropsychopharmacol 17(Suppl 4):S258

    Article  Google Scholar 

  • Snigdha S, Neill JC (2008a) Improvement of phencyclidine-induced social behaviour deficits in rats: involvement of 5-HT(1A) receptors. Behav Brain Res 191:26–31

    Article  PubMed  CAS  Google Scholar 

  • Snigdha S, Neill JC (2008b) Efficacy of antipsychotics to reverse phencyclidine-induced social interaction deficits in female rats—a preliminary investigation. Behav Brain Res 187:489–494

    Article  PubMed  CAS  Google Scholar 

  • Snigdha S, Li Z, Dai J, Shahid M, Neill JC, Meltzer H (2008c) Effect of PCP to attenuate DA efflux in rats performing the object recognition task: an in vivo investigation. Program No. 791.4/TT40. 2008 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2008. Online

  • Sumiyoshi T, Matsui M, Nohara S, Yamashita I, Kurachi M, Sumiyoshi C, Jayathilake K, Meltzer HY (2001) Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 158:1722–1725

    Article  PubMed  CAS  Google Scholar 

  • Sumiyoshi T, Stockmeier CA, Overholser JC, Dilley GE, Meltzer HY (1996) Serotonin1A receptors are increased in post-mortem prefrontal cortex in schizophrenia. Brain Res 708:209–214

    Article  PubMed  CAS  Google Scholar 

  • Sullivan EV, Shear PK, Zipursky RB, Sagar HJ, Pfefferbaum A (1994) A deficit profile of executive, memory, and motor functions in schizophrenia. Biol Psychiatry 36:641–653

    Article  PubMed  CAS  Google Scholar 

  • Sutcliffe JS, Marshall KM, Neill JC (2007) Influence of gender on working and spatial memory in the novel object recognition task in the rat. Behav Brain Res 177:117–25

    Article  PubMed  CAS  Google Scholar 

  • Tait DS, Brown VJ (2007) Difficulty overcoming learned non-reward during reversal learning in rats with ibotenic acid lesions of orbital prefrontal cortex. Ann N Y Acad Sci 1121:407–420

    Article  PubMed  CAS  Google Scholar 

  • Tauscher J, Kapur S, Verhoeff PLG, Hussey DF, Daskalakis ZJ et al (2002) Brain serotonin 5-HT1A receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635. Arch Gen Psychiatry 59:514–520

    Article  PubMed  CAS  Google Scholar 

  • Thomas DR, Hagan JJ (2004) 5-HT7 receptors. Curr Drug Targets CNS Neurol Disord 3:81–90

    Article  PubMed  CAS  Google Scholar 

  • Thomas DR, Atkinson PJ, Hastie PG, Roberts JC, Middlemiss DN, Price GW (2002) [3H]-SB-269970 radiolabels 5-HT7 receptors in rodent, pig and primate brain tissues. Neuropharmacology 42:74–81

    Article  PubMed  CAS  Google Scholar 

  • Varnäs K, Thomas DR, Tupala E, Tiihonen J, Hall H (2004) Distribution of 5-HT7 receptors in the human brain: a preliminary autoradiographic study using [3H]SB-269970. Neurosci Lett 367:313–316

    Article  PubMed  CAS  Google Scholar 

  • Wedzony K, Mackowiak M, Zajaczkowski W, Fijal K, Chocyk A, Czyrak A (2000) WAY100135, an antagonist of 5-HT1A serotonin receptors, attenuates psychotomimetic effects of MK-801. Neuropsychopharmacology 23:547–559

    Article  PubMed  CAS  Google Scholar 

  • Wood MD, Reavill C, Trail B, Wilson A, Stean T, Kennett GA et al (2001) SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety. Neuropharmacology 41:186–199

    Article  PubMed  CAS  Google Scholar 

  • Zhang ZJ, Reynolds GP (2002) A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia. Schizophr Res 55:1–10

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

S.M. is supported by a postgraduate studentship from the University of Bradford and GSK, Harlow, UK.

Author information

Authors and Affiliations

  1. Bradford School of Pharmacy, University of Bradford, Bradford, West Yorkshire, BD7 1DP, UK

    Samantha L. McLean & Joanna C. Neill

  2. GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex, CM19 5AW, UK

    Marie L. Woolley & Dave Thomas

Authors
  1. Samantha L. McLean
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marie L. Woolley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dave Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joanna C. Neill
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joanna C. Neill.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McLean, S.L., Woolley, M.L., Thomas, D. et al. Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat. Psychopharmacology 206, 403–414 (2009). https://doi.org/10.1007/s00213-009-1618-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-009-1618-0

Keywords

Search

Navigation